Q-omics provides the consensus-scored MAP3K2-DT profile across patient tissues and cancer cell-line models. MAP3K2-DT expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, MAP3K2-DT is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, MAP3K2-DT RNA expression shows 14,497 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, KIRC, and UVM as cancer lineages where MAP3K2-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAP3K2-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAP3K2-DT survival associations across molecular data types. MAP3K2-DT RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAP3K2-DT RNA expression–survival associations across cancer types. High MAP3K2-DT expression shows unfavorable associations in KIRC, UVM and KIRP, but favorable associations in SKCM, OV and UCS. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for MAP3K2-DT RNA expression.
This table summarizes MAP3K2-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MAP3K2-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAP3K2-DT shows higher tumor expression in KIRC, LUAD, LIHC, STAD, KIRP and HNSC. The KIRC box plot shows higher MAP3K2-DT RNA expression in tumor versus normal tissue (log2 FC = +0.773, t-test p < 0.001).
This table shows molecular features associated with MAP3K2-DT in patient tissues and cancer cell lines. In patient samples, MAP3K2-DT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
